Could Docetaxel Have Role in Unfavorable-Risk Prostate Cancer?
Adding docetaxel to androgen deprivation therapy (ADT) plus radiation therapy (RT) failed to improve survival in unfavorable-risk prostate cancer, though the combination may hold benefit for certain patients, long-term results of a randomized trial found. While the regimen did not prolong overall survival (OS) among all men with unfavorable-risk nonmetastatic cancer after a median of […]